Cargando…
Folate-Targeted Nanoliposomal Chemophototherapy
Light-responsive liposomes have been developed for the on-demand release of drugs. However, efficient delivery of chemotherapeutic drugs to tumor for cancer theranostics remains a challenge. Herein, folic acid (FA), an established ligand for targeted drug delivery, was used to decorate light-sensiti...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10609802/ https://www.ncbi.nlm.nih.gov/pubmed/37896144 http://dx.doi.org/10.3390/pharmaceutics15102385 |
_version_ | 1785128100434018304 |
---|---|
author | Chitgupi, Upendra Qin, Yiru Ghosh, Sanjana Quinn, Breandan Carter, Kevin He, Xuedan Sunar, Ulas Lovell, Jonathan F. |
author_facet | Chitgupi, Upendra Qin, Yiru Ghosh, Sanjana Quinn, Breandan Carter, Kevin He, Xuedan Sunar, Ulas Lovell, Jonathan F. |
author_sort | Chitgupi, Upendra |
collection | PubMed |
description | Light-responsive liposomes have been developed for the on-demand release of drugs. However, efficient delivery of chemotherapeutic drugs to tumor for cancer theranostics remains a challenge. Herein, folic acid (FA), an established ligand for targeted drug delivery, was used to decorate light-sensitive porphyrin-phospholipid (PoP) liposomes, which were assessed for FA-targeted chemophototherapy (CPT). PoP liposomes and FA-conjugated PoP liposomes were loaded with Doxorubicin (Dox), and physical properties were characterized. In vitro, FA-PoP liposomes that were incubated with FA receptor-overexpressing human KB cancer cells showed increased uptake compared to non-targeted PoP liposomes. Dox and PoP contributed towards chemophototherapy (CPT) in vitro, and PoP and FA-PoP liposomes induced cell killing. In vivo, mice bearing subcutaneous KB tumors treated with PoP or FA-PoP liposomes loaded with Dox, followed by 665 nm laser treatment, had delayed tumor growth and improved survival. Dox delivery to tumors increased following laser irradiation for both PoP and FA-PoP liposomes. Thus, while Dox-FA-PoP liposomes were effective following systemic administration and local light irradiation in this tumor model, the FA targeting moiety did not appear essential for anti-tumor responses. |
format | Online Article Text |
id | pubmed-10609802 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106098022023-10-28 Folate-Targeted Nanoliposomal Chemophototherapy Chitgupi, Upendra Qin, Yiru Ghosh, Sanjana Quinn, Breandan Carter, Kevin He, Xuedan Sunar, Ulas Lovell, Jonathan F. Pharmaceutics Article Light-responsive liposomes have been developed for the on-demand release of drugs. However, efficient delivery of chemotherapeutic drugs to tumor for cancer theranostics remains a challenge. Herein, folic acid (FA), an established ligand for targeted drug delivery, was used to decorate light-sensitive porphyrin-phospholipid (PoP) liposomes, which were assessed for FA-targeted chemophototherapy (CPT). PoP liposomes and FA-conjugated PoP liposomes were loaded with Doxorubicin (Dox), and physical properties were characterized. In vitro, FA-PoP liposomes that were incubated with FA receptor-overexpressing human KB cancer cells showed increased uptake compared to non-targeted PoP liposomes. Dox and PoP contributed towards chemophototherapy (CPT) in vitro, and PoP and FA-PoP liposomes induced cell killing. In vivo, mice bearing subcutaneous KB tumors treated with PoP or FA-PoP liposomes loaded with Dox, followed by 665 nm laser treatment, had delayed tumor growth and improved survival. Dox delivery to tumors increased following laser irradiation for both PoP and FA-PoP liposomes. Thus, while Dox-FA-PoP liposomes were effective following systemic administration and local light irradiation in this tumor model, the FA targeting moiety did not appear essential for anti-tumor responses. MDPI 2023-09-26 /pmc/articles/PMC10609802/ /pubmed/37896144 http://dx.doi.org/10.3390/pharmaceutics15102385 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Chitgupi, Upendra Qin, Yiru Ghosh, Sanjana Quinn, Breandan Carter, Kevin He, Xuedan Sunar, Ulas Lovell, Jonathan F. Folate-Targeted Nanoliposomal Chemophototherapy |
title | Folate-Targeted Nanoliposomal Chemophototherapy |
title_full | Folate-Targeted Nanoliposomal Chemophototherapy |
title_fullStr | Folate-Targeted Nanoliposomal Chemophototherapy |
title_full_unstemmed | Folate-Targeted Nanoliposomal Chemophototherapy |
title_short | Folate-Targeted Nanoliposomal Chemophototherapy |
title_sort | folate-targeted nanoliposomal chemophototherapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10609802/ https://www.ncbi.nlm.nih.gov/pubmed/37896144 http://dx.doi.org/10.3390/pharmaceutics15102385 |
work_keys_str_mv | AT chitgupiupendra folatetargetednanoliposomalchemophototherapy AT qinyiru folatetargetednanoliposomalchemophototherapy AT ghoshsanjana folatetargetednanoliposomalchemophototherapy AT quinnbreandan folatetargetednanoliposomalchemophototherapy AT carterkevin folatetargetednanoliposomalchemophototherapy AT hexuedan folatetargetednanoliposomalchemophototherapy AT sunarulas folatetargetednanoliposomalchemophototherapy AT lovelljonathanf folatetargetednanoliposomalchemophototherapy |